What is GLUE's current stock price?

GLUE (Monte Rosa Therapeutics, Inc.) is currently trading at $18.81 with a market cap of $1.22B.

What sector is Monte Rosa Therapeutics, Inc. in?

Monte Rosa Therapeutics, Inc. (GLUE) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is GLUE a good stock to buy?

Analysts have a Buy consensus on GLUE with a price target of $31.75. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

GLUE Monte Rosa Therapeutics, Inc.

Healthcare

$18.81-0.37%ClosedMarket Cap: $1.22B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.36

P/S

28.52

EV/EBITDA

-7.89

DCF Value

$23.34

FCF Yield

-1.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

95.3%

Operating Margin

-345.2%

Net Margin

-302.7%

ROE

-41.0%

ROA

-17.7%

ROIC

-21.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$4.2M	$-44.5M	$—
Q4 null	$2.8M	$-46.1M	$—
FY null	$123.7M	$-38.6M	$—
Q3 null	$12.8M	$-27.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$31.75

Target (Median)

$34.00

Target Range

$22.00 - $37.00

2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

JP MorganOverweight

2026-05-11

GuggenheimBuy

2026-03-18

Wells FargoOverweight

2026-03-18

Piper SandlerOverweight

2026-01-14

GuggenheimBuy

2026-01-08

Trading Activity

Insider Trades

View All

Manning Anthony M.director

SellFri May 22

Manning Anthony M.director

SellFri May 22

Warmuth Markusdirector, officer: President & CEO

SellTue May 05

Warmuth Markusdirector, officer: President & CEO

SellWed Apr 15

Nickson Philipofficer: Chief Business & Legal Officer

SellFri Apr 10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.62

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Peers

DNA